1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Wet (Neovascular / Exudative) Macular Degeneration. This report provides information on the therapeutic development based on the Wet (Neovascular / Exudative) Macular Degeneration dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Insights, 2014
Table of Contents
- Wet (Neovascular / Exudative) Macular Degeneration Overview
- Wet (Neovascular / Exudative) Macular Degeneration Pipeline Therapeutics
- Wet (Neovascular / Exudative) Macular Degeneration Therapeutics under Development by Companies
- Wet (Neovascular / Exudative) Macular Degeneration Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Wet (Neovascular / Exudative) Macular Degeneration Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Wet (Neovascular / Exudative) Macular Degeneration Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Wet (Neovascular / Exudative) Macular Degeneration Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products
- Wet (Neovascular / Exudative) Macular Degeneration - Dormant Products
- Companies Involved in Therapeutics Development for Wet (Neovascular / Exudative) Macular Degeneration
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Monotherapy Products
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Combination Products
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Route of Administration
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Stage and Route of Administration
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Molecule Type
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Stage and Molecule Type
- Wet (Neovascular / Exudative) Macular Degeneration Therapeutics - Discontinued Products
- Wet (Neovascular / Exudative) Macular Degeneration Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Monotherapy Products
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Combination Products
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Route of Administration
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Stage and Route of Administration
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Molecule Type
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the ...

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Glaucoma Therapeutics Market: Overview Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma ...

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The ophthalmic lasers market is projected to reach USD 1,245.4 million by 2021 from USD 970.2 million in 2016, at a CAGR of 5.1%. Increasing prevalence of ophthalmic disorders, increasing prevalence of ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.